AR006519A1 - Formula encapsulada de liberacion prolongada de clorhidrato de venlafaxina, una formula de pelicula de recubrimiento, y el uso de dicha formula encapsuladapara preparar una formulacion de liberacion prolongada - Google Patents

Formula encapsulada de liberacion prolongada de clorhidrato de venlafaxina, una formula de pelicula de recubrimiento, y el uso de dicha formula encapsuladapara preparar una formulacion de liberacion prolongada

Info

Publication number
AR006519A1
AR006519A1 ARP970100883A AR006519A1 AR 006519 A1 AR006519 A1 AR 006519A1 AR P970100883 A ARP970100883 A AR P970100883A AR 006519 A1 AR006519 A1 AR 006519A1
Authority
AR
Argentina
Prior art keywords
formula
prolonged release
encapsulated
prepare
venlafaxine
Prior art date
Application number
Other languages
English (en)
Spanish (es)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21762972&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR006519(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR006519A1 publication Critical patent/AR006519A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ARP970100883 1996-03-25 1997-03-05 Formula encapsulada de liberacion prolongada de clorhidrato de venlafaxina, una formula de pelicula de recubrimiento, y el uso de dicha formula encapsuladapara preparar una formulacion de liberacion prolongada AR006519A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1400696P 1996-03-25 1996-03-25

Publications (1)

Publication Number Publication Date
AR006519A1 true AR006519A1 (es) 1999-09-08

Family

ID=21762972

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970100883 AR006519A1 (es) 1996-03-25 1997-03-05 Formula encapsulada de liberacion prolongada de clorhidrato de venlafaxina, una formula de pelicula de recubrimiento, y el uso de dicha formula encapsuladapara preparar una formulacion de liberacion prolongada

Country Status (34)

Country Link
EP (2) EP0797991B1 (enExample)
JP (2) JP4771565B2 (enExample)
KR (1) KR101096512B1 (enExample)
CN (2) CN1090018C (enExample)
AR (1) AR006519A1 (enExample)
AT (1) ATE257011T1 (enExample)
AU (1) AU727653B2 (enExample)
BR (1) BR9701304A (enExample)
CA (1) CA2199778C (enExample)
CO (1) CO4761054A1 (enExample)
CY (1) CY2442B1 (enExample)
CZ (1) CZ291637B6 (enExample)
DE (1) DE69727000T2 (enExample)
DK (1) DK0797991T3 (enExample)
EG (1) EG24198A (enExample)
ES (1) ES2210454T3 (enExample)
HU (1) HU224617B1 (enExample)
IL (1) IL120382A (enExample)
IN (1) IN187337B (enExample)
NO (2) NO320355B1 (enExample)
NZ (1) NZ314442A (enExample)
PA (1) PA8426401A1 (enExample)
PE (1) PE57198A1 (enExample)
PL (2) PL188444B1 (enExample)
PT (1) PT797991E (enExample)
PY (1) PY970019A (enExample)
RU (1) RU2176912C2 (enExample)
SK (1) SK281530B6 (enExample)
SV (1) SV1997000015A (enExample)
TR (1) TR199700190A2 (enExample)
TW (1) TW493993B (enExample)
UA (1) UA44904C2 (enExample)
UY (1) UY24613A1 (enExample)
ZA (1) ZA972403B (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE57198A1 (es) * 1996-03-25 1998-10-10 American Home Prod Formula de liberacion prolongada
US6274171B1 (en) 1996-03-25 2001-08-14 American Home Products Corporation Extended release formulation of venlafaxine hydrochloride
UA77145C2 (en) * 1997-11-05 2006-11-15 Wyeth Corp Extended release dosage formulation
JP3379461B2 (ja) * 1998-08-06 2003-02-24 三菱電機株式会社 コア部材の積層金型装置、コア部材の積層方法および電動機
ES2290027T3 (es) * 1999-05-20 2008-02-16 Elan Corporation, Plc Formulaciones multiparticuladas y de liberacion controlada de inhibidores selectivos de la recaptacion de serotonina.
IE990406A1 (en) 1999-05-20 2000-12-27 Elan Corp Plc Multiparticulate controlled release selective serotonin reuptake inhibitor formulations.
ES2162746B1 (es) * 1999-10-21 2003-02-16 Lipotec Sa Microcapsulas para la estabilizacion de productos cosmeticos, farmaceuticos o de alimentacion.
FR2805462B1 (fr) * 2000-02-24 2003-08-15 Therabel Res Nouvelle forme galenique orale a liberation prolongee de la molsidomine
US6482440B2 (en) * 2000-09-21 2002-11-19 Phase 2 Discovery, Inc. Long acting antidepressant microparticles
GB0025208D0 (en) * 2000-10-13 2000-11-29 Euro Celtique Sa Delayed release pharmaceutical formulations
KR20030059206A (ko) * 2000-10-19 2003-07-07 테바 파마슈티컬 인더스트리즈 리미티드 결정질 벤라팍신 염기 및 벤라팍신 히드로클로라이드의신규한 다형태, 이의 제조 방법
SE0102888D0 (sv) * 2001-08-29 2001-08-29 Astrazeneca Ab New formulation
SE0102887D0 (sv) * 2001-08-29 2001-08-29 Astrazeneca Ab New formulation
SE0102886D0 (sv) * 2001-08-29 2001-08-29 Astrazeneca Ab New formulation
IL146462A (en) * 2001-11-13 2015-02-26 Lycored Bio Ltd Prolonged-release preparations containing as an active compound and analapaxin hydrochloride
HUP0104872A3 (en) * 2001-11-13 2004-04-28 Egis Gyogyszergyar Nyilvanosan New polymorphic forms of venlafaxine, process for their preparation, pharmaceutical compositions containing them and their use
WO2003082804A1 (en) 2002-03-28 2003-10-09 Synthon B.V. Venlafaxine besylate
AR039162A1 (es) * 2002-03-28 2005-02-09 Synthon Bv Formulaciones de venlafaxina de liberacion extendida
AU2003226751A1 (en) * 2002-03-28 2003-10-13 Synthon B.V. Low water-soluble venlafaxine salts
EP1596837A2 (en) * 2003-02-07 2005-11-23 Omega Farma Ehf Sustained release formulations of venlafaxine
TW200503670A (en) * 2003-03-28 2005-02-01 Sandoz Ag Venlafaxine compositions
EP1473030B2 (en) * 2003-05-02 2014-05-14 Dexcel Ltd. Extended release Venlafaxine tablet formulation
IN2003MU00504A (enExample) * 2003-06-05 2005-05-13 Alembic Ltd
EP2112920B1 (en) 2003-06-26 2018-07-25 Intellipharmaceutics Corp. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
DK1502587T3 (da) 2003-07-30 2007-01-02 Pharmathen Sa Formulering med vedvarende frigivelse af venlafaxinhydrochlorid
WO2005048979A2 (en) * 2003-10-06 2005-06-02 Torrent Pharmaceuticals Limited Pharmaceutical composition having casing with multiple micro tablets
HUP0303382A2 (hu) * 2003-10-10 2005-08-29 EGIS Gyógyszergyár Rt. Venlafaxin-hidroklorid-tartalmú pelletek
EP1523979A1 (en) * 2003-10-13 2005-04-20 Wyeth Extended release pharmaceutical dosage form
EP1523981A1 (en) * 2003-10-13 2005-04-20 Wyeth Extended release formulations of venlafaxine
DE10359154A1 (de) 2003-12-16 2005-07-28 Krka Tovarna Zdravil, D.D. Verfahren zur Herstellung von Venlafaxin und Venlafaxinhydrochlorid der Form I
WO2005074895A1 (en) 2004-02-04 2005-08-18 Alembic Limited Extended release coated microtablets of venlafaxine hydrochloride
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US7776358B2 (en) 2004-07-22 2010-08-17 Synthon Ip Inc. Extended release venlafaxine besylate tablets
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
CN100463676C (zh) * 2004-11-11 2009-02-25 成都康弘药业集团股份有限公司 一种盐酸文拉法辛控释片制剂及其制备方法
ITFI20050206A1 (it) * 2005-09-30 2007-04-01 Valpharma Sa Composizione farmaceutica a rilascio controllato di venlafaxina cloridrato, e processo per la sua preparazione
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
WO2007112581A1 (en) * 2006-04-03 2007-10-11 Isa Odidi Controlled release delivery device comprising an organosol coat
JP5826456B2 (ja) 2006-04-26 2015-12-02 アルファファーム ピーティーワイ リミテッド コーティングされていない分離したユニットおよび延長放出マトリクスを含む制御放出配合物
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
KR100791194B1 (ko) * 2006-06-12 2008-01-02 코오롱제약주식회사 염산 벤라팍신의 경구 투여용 서방성 펠렛 및 그 제조방법
EP2531181B1 (en) * 2010-02-03 2019-04-10 Pharma Two B Ltd. Extended release formulations of rasagiline and uses thereof
WO2011132008A2 (en) 2010-04-22 2011-10-27 EGIS Gyűgyszergyár Nyilvánosan Múködő Részvény társaság Controlled release pharmaceutical composition
WO2012104852A1 (en) 2011-01-31 2012-08-09 Serotech, Llc Dosage regimen, medication dispensing package and uses thereof for the treatment of major depressive disorder
CN103893151B (zh) * 2012-12-31 2018-04-27 石药集团中奇制药技术（石家庄）有限公司 一种盐酸文拉法辛缓释胶囊及其制备方法
US12042566B2 (en) 2017-05-17 2024-07-23 Confluence Pharmaceuticals, Llc Formulations of homotaurines and salts thereof
CN114288273B (zh) * 2022-02-11 2022-10-18 桂林华信制药有限公司 一种盐酸文拉法辛缓释胶囊及其生产工艺
JP2023127913A (ja) * 2022-03-02 2023-09-14 共和薬品工業株式会社 ベンラファキシン塩酸塩含有顆粒
KR20250121244A (ko) 2024-02-03 2025-08-12 교와 야쿠힝 고교 가부시키가이샤 벤라팍신염산염 함유 서방성 과립의 제조 방법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1561204A (en) * 1977-06-01 1980-02-13 Ici Ltd Sustained release pharmaceutical composition
US4369172A (en) * 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
IE56324B1 (en) * 1982-12-13 1991-06-19 American Home Prod Phenethylamine derivatives and intermediates therefor
US4535186A (en) 1983-04-19 1985-08-13 American Home Products Corporation 2-Phenyl-2-(1-hydroxycycloalkyl or 1-hydroxycycloalk-2-enyl)ethylamine derivatives
US4761501A (en) * 1983-10-26 1988-08-02 American Home Products Corporation Substituted phenylacetamides
IE60311B1 (en) 1987-09-24 1994-06-29 American Home Prod Sustained release etodolac
US6440457B1 (en) * 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
ES2304041T3 (es) * 1993-06-28 2008-09-01 Wyeth Nuevos tratamientos que utilizan derivados de fenetilamina.
TW344661B (en) * 1993-11-24 1998-11-11 Lilly Co Eli Pharmaceutical composition for treatment of incontinence
PE57198A1 (es) * 1996-03-25 1998-10-10 American Home Prod Formula de liberacion prolongada

Also Published As

Publication number Publication date
RU2176912C2 (ru) 2001-12-20
AU727653B2 (en) 2000-12-21
ES2210454T3 (es) 2004-07-01
NZ314442A (en) 1999-06-29
PA8426401A1 (es) 2000-05-24
MX9701873A (es) 1997-09-30
ZA972403B (en) 1998-09-21
ATE257011T1 (de) 2004-01-15
NO971206L (no) 1997-09-26
DK0797991T3 (da) 2004-04-05
IL120382A0 (en) 1997-07-13
CA2199778A1 (en) 1997-09-25
SV1997000015A (es) 1997-08-13
IN187337B (enExample) 2002-03-30
EG24198A (en) 2008-10-14
EP0797991B1 (en) 2004-01-02
SK281530B6 (sk) 2001-04-09
DE69727000T2 (de) 2004-06-09
HK1056686A1 (en) 2004-02-27
NO320355B1 (no) 2005-11-28
HUP9700589A2 (en) 1997-09-29
HUP9700589A3 (en) 2001-03-28
DE69727000D1 (de) 2004-02-05
UA44904C2 (uk) 2002-03-15
CN1403077A (zh) 2003-03-19
JP4771565B2 (ja) 2011-09-14
EP2881110A1 (en) 2015-06-10
PL195564B1 (pl) 2007-10-31
CY2442B1 (en) 2004-11-12
NO971206D0 (no) 1997-03-14
KR101096512B1 (ko) 2014-11-28
IL120382A (en) 2003-06-24
PY970019A (es) 2006-07-03
PE57198A1 (es) 1998-10-10
HU224617B1 (hu) 2005-11-28
TW493993B (en) 2002-07-11
HU9700589D0 (en) 1997-05-28
CZ77297A3 (en) 1997-11-12
SK30197A3 (en) 1997-10-08
UY24613A1 (es) 2000-09-29
PL188444B1 (pl) 2005-02-28
KR970064599A (ko) 1997-10-13
CN1164389A (zh) 1997-11-12
TR199700190A2 (xx) 1997-10-21
EP0797991A1 (en) 1997-10-01
CZ291637B6 (cs) 2003-04-16
CN1090018C (zh) 2002-09-04
PT797991E (pt) 2004-05-31
JP2008156374A (ja) 2008-07-10
AU1640097A (en) 1997-10-02
PL318954A1 (en) 1997-09-29
NO20050379L (no) 1997-09-26
CO4761054A1 (es) 1999-04-27
JPH107552A (ja) 1998-01-13
BR9701304A (pt) 1998-09-29
CA2199778C (en) 2005-12-20

Similar Documents

Publication Publication Date Title
AR006519A1 (es) Formula encapsulada de liberacion prolongada de clorhidrato de venlafaxina, una formula de pelicula de recubrimiento, y el uso de dicha formula encapsuladapara preparar una formulacion de liberacion prolongada
UY25234A1 (es) Formulación de liberación prolongada de venlafaxina
MY142403A (en) Oral dosage forms for propiverine or its pharmaceutically acceptable salts with an extended release of the active ingredient
AR002754A1 (es) Composición farmacéutica que comprende bacterias lactobacillus viables micro-encapsuladas, y uso de la composición para preparar de un medicamento
ES2088312T3 (es) Formulacion de liberacion controlada que contiene tramadol.
BR0107869A (pt) Composições farmacêuticas eletrogiradas
NO20011471D0 (no) Nye orale vedvarende frigivelsesformuleringer
ES2072447T3 (es) Locion analgesica externa y procedimiento de preparacion.
UA26455C2 (uk) Лікарський препарат у формі таблеток із сповільhеhим вивільhеhhям активhого іhгредієhта
AR022008A1 (es) Una composicion de liberacion controlada de galantamina, un proceso para la preparacion de la misma, y el uso de dicha composicion para la preparacion de un medicamento
CO5261556A1 (es) Composiciones inhibidoras de ciclooxigenasa-2 que tiene rapido acceso de efecto terapeutico
ECSP045102A (es) Formulación farmacéutica que contiene 3-(3-dimetilamino-1-etil-2-metil-propil)fenol y proporciona una liberación retardada del ingrediente activo
TR199802108T2 (xx) �bandronat i�eren oral farmas�tik bir form�lasyon.
BR0211198A (pt) Composições farmacêuticas e seu uso
BR0107899A (pt) Processo para produzir uma preparação de ingrediente ativo compreendendo ibuprofeno, preparação de ingrediente ativo, uso da mesma, preparação farmacêutica, uso da mesma, processo para produzir formas de dosagem sólidas, e, forma de dosagem sólida
BR0114100A (pt) Formulações de liberação controlada para administração oral
DE60320039D1 (de) Tramadol-formulierungen mit verzögerter freisetzung und 24-stunden-wirksamkeit
ATE199495T1 (de) Pharmazeutische zubereitung zur direktverpressung
AR016473A1 (es) Preparado efervescente y procedimiento para su preparacion
ECSP972046A (es) Formula de liberacion prolongada
ES2164764T3 (es) Excipiente de liberacion sostenida.
ES2078727T3 (es) Composiciones farmaceuticas.
ECSP982704A (es) Formula de liberacion prolongada
DE60112578D1 (de) Pharmazeutische diclofenac-verbindung basierend auf vitamin e, papain und hyaluronidase
BR9912260A (pt) Emplastro contendo um sistema terapêutico transdérmico e dose única para ministração